AU3129993A - Localized oligonucleotide therapy - Google Patents
Localized oligonucleotide therapyInfo
- Publication number
- AU3129993A AU3129993A AU31299/93A AU3129993A AU3129993A AU 3129993 A AU3129993 A AU 3129993A AU 31299/93 A AU31299/93 A AU 31299/93A AU 3129993 A AU3129993 A AU 3129993A AU 3129993 A AU3129993 A AU 3129993A
- Authority
- AU
- Australia
- Prior art keywords
- oligonucleotide therapy
- localized
- localized oligonucleotide
- therapy
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US792146 | 1977-04-29 | ||
US79214691A | 1991-11-08 | 1991-11-08 | |
US85541692A | 1992-03-18 | 1992-03-18 | |
US855416 | 1992-03-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU3129993A true AU3129993A (en) | 1993-06-07 |
Family
ID=27121241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU31299/93A Abandoned AU3129993A (en) | 1991-11-08 | 1992-11-05 | Localized oligonucleotide therapy |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3129993A (en) |
WO (1) | WO1993008845A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6933286B2 (en) | 1991-03-19 | 2005-08-23 | R. Martin Emanuele | Therapeutic delivery compositions and methods of use thereof |
US7202225B1 (en) | 1993-10-15 | 2007-04-10 | Emanuele R Martin | Therapeutic delivery compositions and methods of use thereof |
US5646042A (en) * | 1992-08-26 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | C-myb targeted ribozymes |
US5658780A (en) * | 1992-12-07 | 1997-08-19 | Ribozyme Pharmaceuticals, Inc. | Rel a targeted ribozymes |
AU685080B2 (en) * | 1993-01-07 | 1998-01-15 | Thomas Jefferson University | Antisense inhibition of C-MYC to modulate the proliferation of smooth muscle cells |
JP3819422B2 (en) * | 1993-10-15 | 2006-09-06 | シトリックス コーポレイション | Therapeutic delivery compositions and methods of use thereof |
US6323184B1 (en) | 1993-10-15 | 2001-11-27 | Thomas Jefferson University | Arteriovenous and venous graft treatments: methods and compositions |
US6133242A (en) * | 1993-10-15 | 2000-10-17 | Thomas Jefferson Univerisity | Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes |
CA2184989A1 (en) * | 1994-03-07 | 1995-09-14 | Tsvi Goldenberg | Ribozyme therapy for restenosis |
FR2723697B1 (en) * | 1994-08-17 | 1996-09-20 | Rhone Poulenc Rorer Sa | METHOD OF TREATING RESTENOSIS WITH GENE THERAPY |
US5656611A (en) * | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
ATE508733T1 (en) * | 1996-03-04 | 2011-05-15 | Penn State Res Found | MATERIALS AND METHODS FOR INCREASE CELLULAR INTERNALIZATION |
DE69731763T3 (en) * | 1996-11-27 | 2010-12-30 | Aventis Pharmaceuticals Inc. | A pharmaceutical composition containing a compound having anti-Xa properties and a compound that is a plaque aggregation antagonist |
CA2286304C (en) | 1997-04-10 | 2007-08-07 | Diagnocure Inc. | Pca3, pca3 genes, and methods of use |
EP1117378A2 (en) | 1998-10-05 | 2001-07-25 | The Penn State Research Foundation | Compositions and methods for enhancing receptor-mediated cellular internalization |
ES2260059T3 (en) | 1999-09-29 | 2006-11-01 | Diagnocure Inc. | RNA MESSENGER OF PCA3 IN BENIGN AND MALIGNED PROSTATE FABRICS. |
GB0018307D0 (en) | 2000-07-26 | 2000-09-13 | Aventis Pharm Prod Inc | Polypeptides |
MXPA02009481A (en) | 2000-03-31 | 2004-05-14 | Aventis Pharma Inc | Nuclear factor kb inducing factor. |
WO2004070056A2 (en) | 2003-02-07 | 2004-08-19 | Diagnocure Inc. | Method to detect prostate cancer in a sample |
CA2491067A1 (en) | 2004-12-24 | 2006-06-24 | Stichting Katholieke Universiteit | Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer |
EP2049666A2 (en) | 2006-07-28 | 2009-04-22 | Sanofi-Aventis | Composition and method for treatment of tumors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4740463A (en) * | 1984-04-13 | 1988-04-26 | Massachusetts Institute Of Technology | Methods and artificial genes for antagonizing the function of an oncogene |
US4806463A (en) * | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
WO1991003260A1 (en) * | 1989-09-01 | 1991-03-21 | Temple University Of The Commonwealth System Of Higher Education | Antisense oligonucleotides to c-abl proto-oncogene |
US5248670A (en) * | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
WO1991015226A1 (en) * | 1990-04-09 | 1991-10-17 | The American National Red Cross | Rejuvenation compositions and methods for their use |
-
1992
- 1992-11-05 AU AU31299/93A patent/AU3129993A/en not_active Abandoned
- 1992-11-05 WO PCT/US1992/009626 patent/WO1993008845A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO1993008845A1 (en) | 1993-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU3972893A (en) | Gene therapy using the intestine | |
AU5457096A (en) | Gene-transfer-mediated angiogenesis therapy | |
IL117309A0 (en) | Gene transfer-mediated angiogenesis therapy | |
AU3129993A (en) | Localized oligonucleotide therapy | |
ZA9533B (en) | Pentolifylline therapy | |
AU6092794A (en) | Oxime-substituted therapeutic compounds | |
AU4377793A (en) | Alternative receptor therapy | |
AU2838192A (en) | Catheter | |
AU6386390A (en) | Therapeutic necleosides | |
AU1480497A (en) | Cancer treatment | |
GB9509572D0 (en) | Cancer therapy | |
GB9307013D0 (en) | Therapeutic combinations | |
AU2547895A (en) | Therapeutic phenoxyalkylheterocycles | |
GB9308166D0 (en) | Cancer therapy | |
PH31659A (en) | Therapeutic nucleotides. | |
GB9524942D0 (en) | Drug therapy | |
AU6594690A (en) | Therapeutic agents | |
GB9317146D0 (en) | Therapeutic combinations | |
AU1175692A (en) | Effluent treatment | |
GB9310441D0 (en) | Gene therapy | |
AU5165993A (en) | Pp14-based therapy | |
AU2687092A (en) | Fluid treatment | |
AU6177190A (en) | Therapeutic agents | |
GB9520433D0 (en) | Gene therapy | |
GB9521711D0 (en) | Gene therapy |